An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy

Rao, V. U., Pavlov, A., Klearman, M., Musselman, D., Giles, J. T., Bathon, J. M., Sattar, N. and Lee, J. S. (2015) An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy. Arthritis and Rheumatology, 67(2), pp. 372-380. (doi:10.1002/art.38920) (PMID:25332171)

[img]
Preview
Text
168228.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

494kB

Abstract

Objective: To evaluate associations between lipid levels, inflammation, and rheumatoid arthritis (RA) disease activity, at baseline and during treatment, with the risk of major adverse cardiovascular events (MACE) in tocilizumab‐treated patients with RA. Methods: In retrospective post hoc analyses, data were pooled for 3,986 adult patients with moderate to severe RA who received ≥1 dose of tocilizumab (4 mg/kg or 8 mg/kg) intravenously every 4 weeks in randomized controlled trials and extension studies. Cox proportional hazards modeling was used to evaluate associations between baseline characteristics and posttreatment changes in laboratory and disease characteristics (week 24) and change in disease activity and laboratory values from baseline to week 24 with the risk of future MACE during extended followup. Results: We identified 50 independently adjudicated cases of MACE during 14,683 patient‐years of followup (0.34 MACE cases/100 patient‐years). At baseline, age, a history of cardiac disorders, the Disease Activity Score in 28 joints (DAS28), and the total cholesterol:high‐density lipoprotein cholesterol ratio were independently associated with MACE in multivariable models (P < 0.05 for all). During treatment, a higher DAS28 and higher swollen and tender joint counts at week 24 were associated with future MACE. In separate models, greater reductions in the DAS28 and joint counts from baseline to week 24 were inversely associated with future MACE; changes in lipid parameters were not statistically significantly associated with the risk of MACE. Conclusion: In this population of patients treated with tocilizumab, an association was observed between the baseline total cholesterol:high‐density lipoprotein cholesterol ratio and an increased risk of MACE. The risk of MACE while receiving treatment, however, was associated with control of disease activity but not lipid changes. Larger studies are needed to confirm these findings.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Sattar, Professor Naveed
Authors: Rao, V. U., Pavlov, A., Klearman, M., Musselman, D., Giles, J. T., Bathon, J. M., Sattar, N., and Lee, J. S.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
Journal Name:Arthritis and Rheumatology
Publisher:Wiley
ISSN:2326-5191
ISSN (Online):2326-5205
Published Online:20 October 2014
Copyright Holders:Copyright © 2015 Genentech Inc.
First Published:First published in Arthritis and Rheumatology 67(2):372-380
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record